Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs
- 1 February 2011
- Vol. 29 (6) , 1248-1257
- https://doi.org/10.1016/j.vaccine.2010.11.079
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (RO1 AI068961)
This publication has 59 references indexed in Scilit:
- Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoeliiVaccine, 2010
- Recombinant Yellow Fever Vaccine Virus 17D Expressing Simian Immunodeficiency Virus SIVmac239 Gag Induces SIV-Specific CD8 + T-Cell Responses in Rhesus MacaquesJournal of Virology, 2010
- Clinical and Immunological Insights on Severe, Adverse Neurotropic and Viscerotropic Disease following 17D Yellow Fever VaccinationClinical and Vaccine Immunology, 2010
- The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell ResponseThe Journal of Immunology, 2009
- Viruses within theFlaviviridaeDecrease CD4 Expression and Inhibit HIV Replication in Human CD4+ CellsThe Journal of Immunology, 2009
- Risk Maps of Lassa Fever in West AfricaPLoS Neglected Tropical Diseases, 2009
- Yellow fever vaccine induces integrated multilineage and polyfunctional immune responsesThe Journal of Experimental Medicine, 2008
- A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunityPublished by Elsevier ,2007
- Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?Clinical and Experimental Immunology, 2007
- Construction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genesVirology Journal, 2007